Other Mutations: NRG1

NCT04886804: A Study to Test Different Doses of BI 1810631 in People With Different Types of Advanced Cancer (Solid Tumours) With Changes in the HER2 Gene

NCT04886804
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2, NRG1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1a of the study; Patients must have a documented diagnosis of HER2 aberration: overexpression OR gene amplification OR non-synonymous somatic mutation OR gene rearrangement involving HER2 or Neuregulin 1 (NRG1)
Exclusions: 
https://ClinicalTrials.gov/show/NCT04886804

NCT02912949: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

NCT02912949
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NRG1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a metastatic solid tumor malignancy with documented NRG1 gene fusion
Exclusions: Patients with known symptomatic or unstable brain metastases; Patients with leptomeningeal metastases
https://ClinicalTrials.gov/show/NCT02912949

Up ↑